Russell W. Jenkins

Broad Institute — United States

Medicine · Health Sciences

40h-index10.7kcitations247works3.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(109), Cancer Immunotherapy and Biomarkers(72), Immunotherapy and Immune Responses(39), Sphingolipid Metabolism and Signaling(23), Immune cells in cancer(21)

Publications247 total

Ablation of prostaglandin E2 signalling through dual receptor knockout in CAR T cells enhances therapeutic efficacy in solid tumours
Nature Biomedical Engineering·2026Open Access
Tumor-infiltrating lymphocyte therapy generated from melanoma brain metastasis: Proof-of-concept for CNS-derived cellular immunotherapy
Neuro-Oncology·2025
Lymphotoxin-driven cancer cell eradication by tumoricidal CD8 <sup>+</sup> TIL
2025Open Access
371 Lymphotoxin-driven cancer cell eradication by tumoricidal CD8+ TIL
Regular and Young Investigator Award Abstracts·2025Open Access
EXTH-47. Mesothelin is a surface antigen present on human meningioma and can be effectively targeted by CAR T-cells
Neuro-Oncology·2025Open Access
Retention of lysosomal acid sphingomyelinase protects from Niemann-Pick Disease
Neurobiology of Disease·2025Open Access
Design of a potent interleukin-21 mimic for cancer immunotherapy
Science Immunology·2025· 1 citedOpen Access
<scp>LRP2</scp> Expression in Melanoma Is Associated With a Transitory Cell State, Increased T Cell Infiltration, and Is Upregulated by <scp>IFNy</scp> Signaling
Pigment Cell & Melanoma Research·2025Open Access
Intratumoral delivery of 4-1BBL boosts IL-12-triggered anti-glioma immunity
Molecular Therapy·2025· 1 citedOpen Access
Molecular basis for targeting TBK1 in CAR-T cell therapies for cancer
Expert Opinion on Therapeutic Targets·2025· 1 cited
Overcoming resistance to immunotherapy by targeting CD38 in human tumor explants
Cell Reports Medicine·2025· 7 citedOpen Access
Mesothelin is a surface antigen present on human meningioma and can be effectively targeted by CAR T-cells
Neuro-Oncology·2025· 4 citedOpen Access
SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy
Journal for ImmunoTherapy of Cancer·2025· 3 citedOpen Access
Author response for "Patient-Derived Organotypic Tumor Spheroids, Tumoroids, and Organoids: Advancing Immunotherapy Using State-of-the-Art 3D Tumor Model Systems"
2025
Sialylated CD43 is a glyco-immune checkpoint for macrophage phagocytosis
2025· 1 citedOpen Access
CREB5 promotes immunotherapy resistance via tumor-intrinsic collagen matrix deposition
2025Open Access
Multimodal blood based profiling reveals insights into mechanisms of immunotherapy resistance
2025Open Access
Abstract 4128: Mapping the hypoxic regulation of IFNγ and TNFα-mediated kinase pathways in melanoma
Cancer Research·2025
Abstract B034: Overcoming resistance to immunotherapy by targeting CD38 in human tumor explants
Cancer Research·2025
LRP2 expression in melanoma is associated with a transitory cell state, increased T cell infiltration, and is upregulated by IFNγ signaling
2025Open Access
page 1 of 13Next →

Frequent Co-authors

Yusuf A. Hannun(23), David A. Barbie(15), Lina M. Obeid(12), Cloud P. Paweletz(9), Genevieve M. Boland(9), Elena V. Ivanova(7), Amir Reza Aref(7), Christopher J. Clarke(7), Keith T. Flaherty(6), Israel Cañadas(6), Shunsuke Kitajima(6), Daniel Canals(6), Kazuyuki Kitatani(6), Andrew Portell(5), Patrick H. Lizotte(5), Kwok‐Kin Wong(5), Tran C. Thai(5), Bill X. Wu(5), Moshe Sade-Feldman(4), Dennie T. Frederick(4)